AKCEA THERAPEUTICS INC's ticker is AKCA and the CUSIP is 00972L107. A total of 65 filers reported holding AKCEA THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is 1.07 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2019 | $1,057,000 | +20.4% | 37,307 | +28.1% | 0.00% | 0.0% |
Q4 2018 | $878,000 | -56.4% | 29,117 | -49.4% | 0.00% | 0.0% |
Q3 2018 | $2,014,000 | +223.3% | 57,492 | +119.0% | 0.00% | 0.0% |
Q2 2018 | $623,000 | -12.6% | 26,257 | -5.7% | 0.00% | 0.0% |
Q1 2018 | $713,000 | +53.7% | 27,855 | +4.3% | 0.00% | 0.0% |
Q4 2017 | $464,000 | -37.2% | 26,702 | 0.0% | 0.00% | 0.0% |
Q3 2017 | $739,000 | – | 26,702 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Iguana Healthcare Management, LLC | 100,000 | $1,736,000 | 1.13% |
BB BIOTECH AG | 1,248,650 | $21,677,000 | 0.61% |
Virtus ETF Advisers LLC | 18,071 | $314,000 | 0.39% |
Eventide Asset Management | 420,000 | $7,291,000 | 0.38% |
Granahan Investment Management | 194,376 | $3,374,000 | 0.26% |
ALTRINSIC GLOBAL ADVISORS LLC | 150,000 | $2,604,000 | 0.10% |
Candriam S.C.A. | 114,571 | $1,990,000 | 0.03% |
ARDSLEY ADVISORY PARTNERS LP | 15,000 | $260,000 | 0.03% |
Delpha Capital Management, LLC | 1,521 | $26,000 | 0.03% |
FMR LLC | 9,981,244 | $173,274,000 | 0.02% |